Coagulation factor IX is the gatekeeper of the intrinsic clotting pathway. Synthesised in the liver and secreted into the circulation as an inactive zymogen, it is activated by factor XIa to form the tenase complex¹¹ tenase complex
a membrane-assembled enzyme comprising activated factor IX (FIXa), cofactor VIIIa, calcium, and phospholipid that amplifies factor X activation approximately 50,000-fold. Severe loss-of-function mutations in F9 cause haemophilia B. A far more common story is the intronic variant rs422187 — an intron-embedded single nucleotide change sitting 362 bp upstream of exon 5 in the F9 pre-mRNA, with no direct protein-coding consequence. Its relevance comes entirely from what it tracks: the rs6048 missense haplotype (Factor IX Malmö) and its documented modest protection against deep vein thrombosis.

Because F9 sits on the X chromosome (Xq27.1), males are hemizygous — they carry exactly one allele at rs422187. Genotyping chips typically report hemizygous males as homozygous in raw data, so a male reported as AA carries one A allele and a male reported as CC carries one C allele.

The Mechanism

The rs422187 variant sits at chrX:139550700 (GRCh38), 421 bp from the rs6048 coding variant at position 139551121. Its HGVS transcript designation is c.521-362A>C — 362 nucleotides into the intron preceding coding position 521. VEP classifies the consequence as intron_variant with MODIFIER impact, predicting no direct disruption to splicing signals or protein sequence. There is no curated ClinVar entry for this variant, consistent with its designation as a population-level tag SNP rather than a functional variant in its own right.

The striking feature of rs422187 is its near-perfect linkage disequilibrium with rs6048 in European populations: r²=0.94 in the combined LETS and MEGA cohorts²² r²=0.94 in the combined LETS and MEGA cohorts
Bezemer et al. Haematologica 2009;94(5):693–9, and r²=1.0, D'=1.0 in CEU samples from 1000 Genomes Phase 3. The allele frequencies mirror each other precisely — the C allele of rs422187 (≈30% European) co-segregates with the G allele of rs6048 on the same haplotype. This complete co-inheritance means the two variants are functionally indistinguishable at current resolution: any causal effect attributed to rs6048 could in principle be mediated by rs422187 or any other variant in tight LD.

Bezemer and colleagues investigated 28 nearby variants alongside rs6048 in their primary analysis. rs422187 showed "similarly associated" DVT risk to rs6048 itself, but rs6048 emerged as the single most strongly associated variant — suggesting the missense change (Thr194Ala) may be causal, with rs422187 serving as a correlated intron tag. However, since factor IX antigen levels, activation peptide levels, and endogenous thrombin potential did not differ between genotype groups, the mechanism of protective effect — whether attributed to rs6048 or rs422187 — remains genuinely unknown.

The Evidence

The primary association evidence comes from the Bezemer 2009 LETS + MEGA case-control analysis³³ Bezemer 2009 LETS + MEGA case-control analysis
Irene D Bezemer et al. "F9 Malmö, factor IX and deep vein thrombosis." Haematologica 2009;94(5):693–9. Combined n=1,849 men (LETS n=380, MEGA n=1,469). The analysis specifically tested rs422187 among 28 nearby variants and found it in near-perfect LD with rs6048, with comparable DVT association. The lead signal (rs6048 G allele) carried an odds ratio of 0.80 (95% CI 0.69–0.93) for DVT protection. Because of the near-perfect LD, rs422187 C allele carriers show essentially the same risk shift.

This locus was subsequently confirmed in two large GWAS studies. The Klarin 2019 genome-wide study⁴⁴ Klarin 2019 genome-wide study
Derek Klarin et al. "Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease." Nature Genetics 2019;51:1574–1579. Over 650,000 participants, MVP + UK Biobank identified the F9 locus among 33 genomic loci associated with VTE. The Thibord 2022 cross-ancestry meta-analysis⁵⁵ Thibord 2022 cross-ancestry meta-analysis
Florian Thibord et al. "Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors." Circulation 2022;146:1225–1242. 81,669 VTE cases across 30 studies replicated the F9 signal across European, African, and Hispanic populations, confirming the population-generalisable nature of the protective association.

Recurrence risk was addressed by Roach et al. 2015⁶⁶ Roach et al. 2015
REH Roach et al. "The F9 Malmö sequence variant and sex-related differences in recurrence risk in patients with a first VTE." J Thromb Haemost 2015;13(10):1815–22. Four European cohorts: n=2,185, which found that the Factor IX Malmö haplotype did not explain the observed sex difference in VTE recurrence. The modest protective effect appears to apply primarily to first VTE events.

The effect is modest — OR ~0.80, equivalent to roughly a 20% reduction in first DVT odds. It does not approach the magnitude of Factor V Leiden (OR ~5–7 in heterozygotes) or prothrombin G20210A (OR ~3). The C/G allele of this locus is a tilt, not a shield.

Practical Actions

For carriers of one or two C alleles at rs422187, the practical implications parallel those of rs6048. The modest DVT protection shifts baseline probability slightly downward but does not override other thrombophilic risk factors. Standard DVT prevention measures — particularly during surgery, prolonged immobility, or when taking combined hormonal contraceptives — remain important regardless of this variant's protective direction.

For AA homozygotes (the most common genotype in most populations), no specific action is indicated — this genotype represents population-average factor IX pathway function, and the variant itself is non-coding. Other coagulation variants (Factor V Leiden, prothrombin G20210A) carry much larger effect sizes and are the primary determinants of inherited thrombophilia risk.

The most variable population is African (C allele frequency ~57%) versus East Asian (C allele frequency <1%), meaning the protective allele is substantially more common in populations of African ancestry than in European or East Asian populations.

Interactions

rs422187 and rs6048 are in near-perfect LD and should be treated as marking the same haplotype. If both appear in a genetic profile, they are reporting the same underlying signal. The most clinically relevant interactions are with other coagulation variants: Factor V Leiden (rs6025, OR ~5–7 for heterozygotes) and prothrombin G20210A (rs1799963, OR ~3) are the dominant determinants of inherited thrombophilia risk. The modest protective effect of the F9 C allele would partially offset, but not neutralise, the elevated risk conferred by these stronger variants.

Your heart's arteries are constantly cleared of lipoprotein debris by a network of cell-surface receptors. One of these, LRP8 (also called ApoER2)¹¹ LRP8 (also called ApoER2)
LDL receptor-related protein 8, a member of the LDLR superfamily that binds and internalizes ApoE-containing lipoproteins, does double duty: it clears atherogenic particles from the bloodstream and mediates a protective signaling cascade in platelets. The R952Q missense variant disrupts the cytoplasmic tail of this receptor in a way that amplifies inflammatory signaling and blunts platelet regulation — a combination that has been found repeatedly in families with unusually early heart attacks.

The Mechanism

LRP8 is encoded on the minus strand of chromosome 1 (p32.3). The R952Q substitution — a G→A change in the coding sequence (c.2855G>A), reported as C→T on the genomic plus strand — replaces a positively charged arginine with a neutral glutamine in the intracellular domain of the receptor protein. This region contains signaling docking sites; the amino acid swap alters downstream signal transduction without abolishing receptor expression or ligand binding.

Two distinct mechanisms have been described. First, Shen et al. showed²² Shen et al. showed
Shen GQ et al., Am J Hum Genet 2007 that the Q allele increases activation of [p38 MAPK | p38 mitogen-activated protein kinase, a stress-response kinase that promotes inflammatory gene expression including cytokines and matrix metalloproteinases] when vascular cells are exposed to oxidized LDL. Heightened p38 MAPK activity in arterial wall macrophages and smooth muscle cells accelerates plaque formation and destabilization. Second, LRP8 is expressed on the platelet surface where it mediates ApoE3's inhibitory effect on platelet activation. In mice lacking LRP8, platelet aggregation is dysregulated³³ platelet aggregation is dysregulated
Robertson et al., Thromb Res 2009 — ADP and thrombin trigger excessive aggregation, and in-vivo thrombosis time is prolonged 68–200% depending on allele dose, suggesting a paradoxical platelet hyperreactivity under physiological conditions in humans with impaired LRP8 signaling.

The Evidence

The strongest evidence for R952Q as a cardiovascular risk variant comes from studies specifically enriched for familial and premature disease. In the original discovery cohort of 381 patients with premature CAD/MI versus 560 controls, Shen et al. 2007⁴⁴ Shen et al. 2007 found significant association replicated independently in Italian familial MI cases (248 vs 308 controls) and in the pedigree-based GeneQuest II cohort (441 individuals, 22 families). The association was notably absent in a sporadic, non-familial CAD population, consistent with a variant of moderate penetrance that matters most in a familial context.

A larger haplotype analysis identified a five-SNP risk haplotype TACGC⁵⁵ identified a five-SNP risk haplotype TACGC
Shen et al., Circ Cardiovasc Genet 2014 — containing R952Q as one of its five constituent variants — that was present exclusively in CAD/MI patients and absent in controls across the GeneQuest cohort (P=7.4×10⁻⁷ for CAD; P=2.2×10⁻⁹ for MI), with independent replication in Italian and South Korean cohorts. TACGC homozygotes developed disease earlier and had significantly higher LDL cholesterol than heterozygotes (P<0.05).

The MI risk is further amplified when R952Q co-occurs with the APOE ε4 allele. In 681 Italian subjects (394 MI cases, 287 controls), Martinelli et al. 2009⁶⁶ Martinelli et al. 2009 found that the R952Q QQ/ε4 combination carried an OR of 3.88 (95% CI 1.08–13.9) for MI, more than either variant alone, mediated by progressively lower plasma ApoE concentrations (RR: 0.045, RQ: 0.044, QQ: 0.040 g/L; P=0.047 for trend).

Not all replication attempts succeeded. A large German study including WTCCC data (>6,000 subjects across four European cohorts) found no association⁷⁷ found no association
Lieb et al., J Mol Med 2008. The discrepancy is most plausibly explained by population composition: the positive studies specifically recruited familial early-onset cases, while the negative study included predominantly sporadic disease. R952Q appears to be a moderate-penetrance variant whose effect is most visible in family-enriched cohorts where other shared genetic and environmental risk factors amplify its contribution.

Practical Actions

For T-allele carriers, the most actionable findings center on LDL particle quality (smaller, denser LDL particles are more atherogenic), triglycerides, and thrombotic risk. Monitoring these specific lipid fractions — rather than relying solely on standard total cholesterol — provides the most genotype-relevant picture of cardiovascular risk. The platelet biology findings support particular attention to omega-3 fatty acids, which both reduce platelet reactivity through independent mechanisms and lower triglycerides, addressing two of the pathways disrupted by this variant.

Interactions

The strongest documented interaction is with APOE ε4 (rs429358/rs7412). Carriers of both R952Q (rs5174 TT) and APOE ε4 show the lowest plasma ApoE concentrations and the highest MI odds (OR 3.88), because ApoE is both the ligand cleared by LRP8 and the lipid transport protein whose plasma level is genetically modulated by APOE isoform. When LRP8 receptor function is impaired AND ApoE production or clearance is altered by APOE genotype, the combined dysfunction in lipoprotein clearance is additive.

The TACGC haplotype context (rs7546246, rs2297660, rs3737983, R952Q/rs5174, rs5177) also shows that R952Q does not act entirely alone — it is one node in a multi-SNP haplotype, and the haplotype background partially determines the penetrance of the individual Q allele.

Your liver burns fat by routing long-chain fatty acids into mitochondria — the cellular power plants. But fatty acids can't cross the inner mitochondrial membrane on their own. They need a molecular escort. That escort is the carnitine shuttle¹¹ carnitine shuttle
a two-enzyme system that attaches a carnitine molecule to fatty acids, enabling mitochondrial entry, and the enzyme that initiates it — carnitine palmitoyltransferase 1A (CPT1A) — is the rate-limiting bottleneck for all hepatic fat oxidation.

rs613084 is an intronic variant that acts as a cis-regulatory switch for CPT1A expression in liver tissue. Your genotype here influences how much CPT1A your liver produces, which in turn governs how efficiently you clear long-chain fats, influence circulating triglyceride levels, and generate HDL cholesterol.

The Mechanism

CPT1A sits on the outer mitochondrial membrane and catalyzes the acylcarnitine²² acylcarnitine
the carnitine-linked form of a fatty acid that can traverse the mitochondrial membrane conversion step. Its activity is tightly regulated by malonyl-CoA³³ malonyl-CoA
a metabolic intermediate that rises when energy is plentiful, signaling the cell to store rather than burn fat, which binds the enzyme's N-terminal domain and acts as an allosteric brake. When CPT1A expression is higher, more enzyme is available to handle fat-burning demand even under partial malonyl-CoA inhibition; when expression is lower, long-chain fatty acids back up in the cytoplasm and are re-esterified as triglycerides rather than oxidized.

rs613084 lies within CPT1A intron 1 — a genomic region that, based on parallel methylation research in the GOLDN study⁴⁴ GOLDN study
Genetics of Lipid Lowering Drugs and Diet Network — a large family-based study of European-ancestry adults, appears to be a major regulatory hub for CPT1A transcription. Two CpG sites in this same intron associate with fasting triglycerides at genome-wide significance (p=5.3×10⁻¹⁴) and with VLDL-C, adiponectin, insulin, and HOMA-IR. The A allele at rs613084 has been shown to correlate with higher CPT1A transcript levels in a cis-eQTL analysis of Mexican American families (SAFHS cohort).

The Evidence

The primary genetic evidence for rs613084 comes from the GOCADAN study⁵⁵ GOCADAN study
Genetics of Coronary Artery Disease in Alaska Natives, n=761 Alaskan Eskimos, where rs613084 emerged as one of three independent CPT1A variants significantly associated with estimated delta-5 desaturase (D5D) activity — the rate-limiting enzyme for ω-3 and ω-6 fatty acid conversion — at p=6.7×10⁻⁵ for HDL-C and reaching p values as low as 1.6×10⁻⁹ for erythrocyte D5D activity. The A allele associated with higher D5D activity and elevated HDL-C. Importantly, the CPT1A expression association was replicated in Mexican Americans⁶⁶ replicated in Mexican Americans
San Antonio Family Heart Study (SAFHS), a large independent family-based cohort of Mexican-American adults (p=1.14×10⁻⁶²), making this one of the strongest cis-eQTL signals for CPT1A in liver-relevant tissue and confirming the finding across ethnic groups.

The indirect link between CPT1A expression and D5D activity is thought to reflect a shared regulatory network: both enzymes participate in fatty acid flux decisions in the liver, and CPT1A activity influences the availability of fatty acid substrates for FADS-family desaturases. Higher CPT1A expression means more substrate is diverted toward oxidation, which alters the pool available for desaturation and incorporation into phospholipids and lipoproteins — explaining the observed HDL-C effect.

Practical Actions

The A allele at rs613084 is associated with modestly higher CPT1A expression and more efficient hepatic fatty acid oxidation, reflected in higher HDL-C. This variant has no drug interactions and is not pathogenic. Its primary practical relevance is in optimizing dietary fat composition and supporting the carnitine shuttle that CPT1A depends on.

Long-chain fatty acids require L-carnitine as a cofactor for CPT1A-mediated transport. Individuals with lower CPT1A expression (CC genotype) have less enzymatic reserve for fat oxidation and may benefit more from dietary and supplementation strategies that support carnitine availability.

Interactions

rs613084 acts within the same functional network as rs3019594 and rs11228368 — two other independent CPT1A intronic variants identified in the GOCADAN study. Together these three SNPs tag distinct haplotype blocks across the CPT1A intron 1 regulatory region. They may interact additively on expression.

The Arctic-prevalence CPT1A P479L variant (rs80356779) — a missense variant with reduced malonyl-CoA sensitivity and lower catalytic activity — is a distinct functional allele in the same gene with independent population genetics and a separate biological mechanism. Compound effects of rs613084 with rs80356779 have not been formally studied but would be relevant in Arctic-ancestry populations carrying both.

The GC gene encodes vitamin D binding protein (VDBP/DBP)¹¹ vitamin D binding protein (VDBP/DBP)
A 58-kDa glycoprotein produced mainly by the liver that carries 85-90% of all circulating 25(OH)D and 85% of 1,25(OH)₂D in the bloodstream. Less than 1% of vitamin D metabolites circulate unbound (free). Only the free fraction and the smaller albumin-bound fraction are considered biologically available to enter cells, the principal carrier that transports vitamin D metabolites through the blood. rs705117 is an intronic variant in GC that has been independently associated with circulating VDBP concentrations — separate from the well-known isoform-defining variants rs4588 and rs7041. Individuals carrying certain alleles at rs705117 produce systematically lower VDBP, which creates an important paradox: lower total 25(OH)D on a standard blood test may coexist with normal or even elevated free, biologically active vitamin D²² lower total 25(OH)D on a standard blood test may coexist with normal or even elevated free, biologically active vitamin D
The "free hormone hypothesis" holds that only unbound hormone is biologically active. When VDBP is genetically low, a smaller fraction of vitamin D is sequestered, raising the free fraction. The net biological effect depends on how much VDBP is reduced and on other pathway variants.

The Mechanism

rs705117 sits in intron 10 of the GC gene on chromosome 4 (GRCh38 position 71742398). As an intronic variant, it does not alter the VDBP protein sequence directly; instead, it likely influences GC gene transcription or mRNA processing³³ GC gene transcription or mRNA processing
Intronic variants can affect splicing efficiency, polyadenylation signals, or regulatory element binding — all of which modulate how much protein the gene produces without changing its amino acid sequence, resulting in measurably different circulating VDBP concentrations between genotype groups.

In a targeted genome-wide association study of serum VDBP⁴⁴ genome-wide association study of serum VDBP
Moy KA et al. Genome-wide association study of circulating vitamin D-binding protein. Am J Clin Nutr, 2014, rs705117 emerged as one of two independent signals in the GC gene significantly associated with circulating DBP levels (P = 4.7 × 10⁻⁹¹). Mean DBP concentrations differed three-fold across genotype groups. This effect was observed independently of the classical isoform-defining variants (rs7041 Asp432Glu), demonstrating that rs705117 captures a separate component of genetically determined VDBP variation.

The T allele at rs705117 haplotypes with the rs2282679-G allele (the main GWAS signal at the GC locus for lower 25(OH)D) and is part of the GC haplotype TGA⁵⁵ GC haplotype TGA
rs705117-T + rs2282679-G + rs1491710-A; identified in a Chinese haplotype analysis as the risk combination for lower 25(OH)D concentration. Zhang et al. 2013 (PMID 23505139) associated with lower vitamin D levels.

The Evidence

The GWAS by Moy et al. 2014⁶⁶ Moy et al. 2014
Moy KA et al. Genome-wide association study of circulating vitamin D-binding protein. Am J Clin Nutr, 2014;99(6):1424-31 in 1,380 men demonstrated a striking dose-response relationship at rs705117: individuals with 0, 1, or 2 copies of the minor allele had mean VDBP concentrations of 6,339, 4,280, and 2,341 nmol/L, respectively — an approximate three-fold difference between homozygote groups.

A haplotype analysis in 2,897 healthy Chinese subjects⁷⁷ 2,897 healthy Chinese subjects
Zhang Z et al. An analysis of the association between the vitamin D pathway and serum 25-hydroxyvitamin D levels in a healthy Chinese population. J Bone Miner Res, 2013;28(8):1784-92 confirmed rs705117 as part of a GC haplotype associated with lower 25(OH)D (each additional risk allele associated with a 0.12-fold decrease in log-25(OH)D, P = 3.7 × 10⁻¹²). The overall GC locus — encompassing rs705117, rs2282679, rs4588, and rs7041 — is the strongest common genetic determinant of vitamin D status, accounting for approximately 2-7% of variance in 25(OH)D concentrations in most European populations.

The landmark SUNLIGHT consortium GWAS⁸⁸ SUNLIGHT consortium GWAS
Wang TJ et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, 2010;376(9736):180-8 of 33,996 Europeans found that a composite genetic risk score combining GC and two other loci conferred an OR of 2.47 (95% CI 2.20-2.78) for vitamin D insufficiency. rs705117 sits within the same GC region.

The free-vitamin-D paradox has clear clinical implications: a review by Jassil et al. 2017⁹⁹ Jassil et al. 2017
Jassil NK et al. Vitamin D binding protein and 25-hydroxyvitamin D levels: emerging clinical applications. Endocr Pract, 2017;23(5):605-13 confirms that because less than 1% of vitamin D circulates unbound, any genetic reduction in VDBP necessarily shifts the free-to-total ratio — meaning standard serum 25(OH)D measurements systematically underestimate available vitamin D in low-VDBP carriers.

Practical Implications

TT carriers face a decision point when their serum 25(OH)D comes back in the borderline range (20-30 ng/mL or 50-75 nmol/L): the result may reflect genetically lower VDBP concentration rather than true vitamin D deficiency. Requesting a free 25(OH)D measurement alongside the standard total test provides a more complete picture. When supplementing, TT carriers should target the mid-range of the sufficiency window (40-60 ng/mL total) rather than pushing to the upper limit, since their free fraction may already be adequate.

Interactions

rs705117 operates within the same GC gene as rs4588 (Thr436Lys, isoform-defining) and rs7041 (Asp432Glu, isoform-defining), and is in partial linkage disequilibrium with the GWAS tag SNP rs2282679. The T allele at rs705117 co-haplotypes with the lower-VDBP alleles at these neighboring variants, compounding their effects. A carrier of both rs705117-TT and rs4588-TT (Gc2/Gc2) will have substantially lower total 25(OH)D than either variant alone predicts, with the greatest potential discordance between total and free vitamin D status.

Downstream, the practical effect of low VDBP intersects with the VDR receptor (rs2228570 / rs1544410) and the 25-hydroxylase CYP2R1 (rs10741657). If hepatic activation of vitamin D is also reduced (CYP2R1 risk allele), lower VDBP compounds the insufficiency because there is less 25(OH)D to distribute in the first place.

Inside every cell, folate is trapped in a useful form: attached to chains of glutamate molecules called polyglutamates¹¹ polyglutamates
Polyglutamate tails: chains of glutamic acid added to folate molecules that anchor them inside cells, making folate more concentrated and metabolically active than the free monoglutamate form that circulates in blood. This trapping is essential — polyglutamated folate is the working form that enzymes in the methylation cycle and nucleotide synthesis actually use. GGH (gamma-glutamyl hydrolase) is the enzyme that cuts these glutamate chains off, converting polyglutamates back to monoglutamates that can leave the cell. The -124T>G promoter variant (rs11545076) increases GGH expression, meaning more of this enzyme is produced — which speeds up the hydrolysis of intracellular folate stores and reduces how much folate the cell can retain.

The Mechanism

The GGH gene sits on chromosome 8q12.3 on the minus (reverse) strand. Its promoter controls how much GGH protein is made. The rs11545076 variant is a T-to-G change at position -124 relative to the translation start (described in papers as coding-strand notation; on the genomic plus strand, this appears as an A-to-C change). Luciferase reporter assays²² Luciferase reporter assays
DeVos et al., 2003 — Identification of SNPs in GGH, Mutat Res 2003 in HepG2 (liver) and MCF-7 (breast) cells showed that the -124G allele significantly increased promoter activity compared to the wild-type -124T allele. Higher GGH activity accelerates the cleavage of polyglutamylated folate to monoglutamylated folate, which is then exported from the cell. The net effect is reduced intracellular folate retention — less folate available for thymidylate synthesis³³ thymidylate synthesis
Thymidylate synthesis: the biochemical pathway that makes thymidine (T), one of the four DNA bases. Folate is the methyl donor in this reaction; folate shortage leads to uracil being misincorporated in place of thymine and methylation reactions.

The Evidence

The clearest human evidence comes from a study of 899 adults⁴⁴ study of 899 adults
DeVos L et al. Associations between SNPs in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil. Am J Clin Nutr, 2008 measuring DNA uracil content — a sensitive marker of intracellular folate sufficiency, since folate shortage causes uracil to be misincorporated into DNA instead of thymidine. Carriers of one C allele (AC genotype; TG in coding notation) had 30% higher DNA uracil levels than AA homozygotes; those with two C alleles (CC; GG in coding notation) had 73% higher DNA uracil (P for trend = 0.022). Crucially, this effect was independent of plasma folate and plasma homocysteine levels — meaning standard blood tests for folate status would appear normal even when intracellular folate is depleted at the cellular level.

In a cohort of 471 Singapore Chinese adults⁵⁵ cohort of 471 Singapore Chinese adults
Oppeneer SJ et al. Genetic variation in FPGS and GGH and plasma homocysteine. Mol Genet Metab, 2012, rs11545076 showed the strongest association with plasma homocysteine of nine GGH variants tested, and was the only variant to survive multiple-comparisons correction (adjusted p=0.001). Interestingly, carriers of the G allele (AC/CC genotypes) had slightly lower — not higher — homocysteine than TT homozygotes (GT: 9.3 nmol/L vs TT: 10.1 nmol/L). This apparent paradox may reflect compensatory redistribution of folate pools: when intracellular retention is reduced, more folate circulates in plasma, potentially supporting remethylation of homocysteine via methionine synthase.

Experimental manipulation of GGH expression in cancer cell lines confirms the downstream methylation effects⁶⁶ confirms the downstream methylation effects
Kim YI et al. γ-Glutamyl hydrolase modulation significantly influences global and gene-specific DNA methylation. Genes Nutr, 2015: GGH overexpression decreased global DNA methylation by 16-22% and reduced DNMT (DNA methyltransferase) activity, while GGH inhibition increased global DNA methylation by 7-15%. These findings establish a direct mechanistic link between GGH activity, intracellular folate retention, and epigenetic regulation.

Practical Actions

The C allele (G in coding notation) increases GGH expression and accelerates intracellular folate depletion. Because plasma folate levels may appear normal despite cellular depletion, standard serum folate tests can miss this effect. Optimizing dietary folate intake from natural sources (leafy greens, legumes, liver) — which arrives as polyglutamates that may be better retained even with elevated GGH — is preferable to relying solely on folic acid supplements. Methylfolate (5-MTHF) supplementation directly provides the active form without requiring intracellular conversion. Monitoring DNA methylation markers or homocysteine as a proxy for folate cycle function may help assess personal folate sufficiency. Individuals carrying the C allele who also have impaired folate conversion (MTHFR C677T) face a compound challenge: reduced conversion capacity plus accelerated intracellular depletion.

Interactions

The most clinically significant interaction is with MTHFR C677T (rs1801133). GGH accelerates cellular folate export while MTHFR C677T impairs conversion of dietary folate to the active methylfolate form. Together, AC or CC at rs11545076 combined with AG or AA at rs1801133 creates a compound reduction in effective intracellular folate: the cell receives less active folate due to impaired conversion, AND retains it less efficiently due to elevated GGH activity. This combination may warrant higher methylfolate doses than either variant alone.

GGH also controls intracellular levels of methotrexate polyglutamates. The related variant rs11545078 (GGH c.452C>T, coding region) reduces GGH activity and paradoxically increases MTX polyglutamate accumulation, causing methotrexate toxicity — the opposite direction from rs11545076. These two variants can co-occur and have opposing effects on methotrexate efficacy. The promoter variant rs3758149 (-401C>T, also listed as C-401T) has similar direction effects to rs11545076 and is in partial linkage disequilibrium.

IGF2BP2 is an mRNA-binding protein with an unusual job: it acts as a post-transcriptional regulator of insulin-like growth factor 2 (IGF2), a signaling molecule critical for pancreatic development, beta cell survival, and adipose tissue metabolism. The rs11705701 variant sits about 2 kilobases upstream of the gene and subtly rewires how IGF2BP2 protein is produced — not eliminating it, but shifting which version of the protein dominates in key metabolic tissues.

The Mechanism

The IGF2BP2 gene produces two major protein isoforms: p66 (the full-length form with both RNA-binding domains intact) and p58 (a shorter isoform lacking the N-terminal RRM1 domain). These isoforms are not functionally equivalent. The p58 isoform appears to act as a post-transcriptional brake¹¹ post-transcriptional brake
A regulatory mechanism that modulates how much IGF2 protein is produced from existing mRNA transcript, helping to tune IGF2 output at the tissue level.

The A allele at rs11705701 shifts this balance: research in visceral adipose tissue²² research in visceral adipose tissue
Grishina et al. IGF2BP2 mRNA and protein levels in adipose tissue. Review of Diabetic Studies, 2013 shows that AA homozygotes have reduced p58 and elevated p66 levels. Because p58 lacks the first RNA-recognition motif, reduced p58 availability may disinhibit IGF2 mRNA translation, dysregulating the IGF2 signaling axis in adipose and islet tissue.

IGF2BP2 also functions as an m6A reader³³ m6A reader
A protein that recognizes and binds to N6-methyladenosine modifications on mRNA, a major form of epitranscriptomic regulation — it directly binds PDX1 mRNA (a master transcription factor for beta cell identity) and stimulates its translation. Pancreatic beta-cell-specific knockout studies⁴⁴ Pancreatic beta-cell-specific knockout studies
PMC8076713 — IMP2 deletion reduces compensatory beta cell proliferation by 70% and impairs glucose-stimulated insulin secretion show that loss of IGF2BP2 function dramatically impairs beta cell proliferation and insulin secretion, establishing the gene's critical role in islet homeostasis.

The Evidence

The clearest functional evidence comes from a Russian case-control study (n=2,917)⁵⁵ Russian case-control study (n=2,917)
Grishina et al. Review of Diabetic Studies, 2013 in which the A allele was associated with T2D risk (OR=1.19, p<0.001). In non-diabetic AA homozygotes, the metabolic phenotype was already visible: higher HOMA-IR (p=0.04), lower HOMA-β (p=0.012), and reduced two-hour insulin levels (p=0.016) — hallmarks of combined insulin resistance and early secretory insufficiency.

A European study using hyperglycaemic clamps⁶⁶ hyperglycaemic clamps
A gold-standard technique that holds blood glucose at a fixed elevated level while measuring insulin secretion in real time found that IGF2BP2 variants were associated with a 28% reduction in first-phase insulin secretion⁷⁷ 28% reduction in first-phase insulin secretion
Staiger et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion. Diabetologia, 2008 (n=272 NGT/IGT subjects, Netherlands and Germany), placing IGF2BP2 among the genes where T2D risk is mediated primarily through beta cell dysfunction rather than peripheral insulin resistance alone.

In Mexican Americans from the BetaGene family study (n=717), rs11705701 showed a significant interaction with adiposity⁸⁸ rs11705701 showed a significant interaction with adiposity
Knowles et al. Variation in IGF2BP2 interacts with adiposity to alter insulin sensitivity. Diabetes, 2015: each A allele was associated with ~1.5–2% lower body fat percentage. However, at higher adiposity, AA homozygotes showed the steepest decline in insulin sensitivity — meaning the A allele's effect on insulin signaling appears to be amplified by excess body fat.

Evidence is not uniformly positive. A Chinese prediabetes study (n=1,536) found an association only in females under a dominant model, and a 2024 gestational diabetes study (n=1,703) found no significant association⁹⁹ found no significant association
Zheng et al. PLoS One, 2024 for rs11705701 specifically. The variant may be a proxy marker for a nearby causal variant rather than functional itself, and population-specific LD patterns explain some of the heterogeneity across ethnicities.

Overall, the evidence supports a moderate classification: replicated signal in multiple populations and datasets, plausible mechanistic basis, but inconsistent across ethnicities and short of clinical-grade evidence.

Practical Implications

The combined phenotype — reduced beta cell reserve combined with impaired insulin sensitivity that worsens with adiposity — defines the actionable target: keep visceral fat low enough that the metabolic interaction stays in the favorable zone. This variant specifically identifies carriers who are likely to convert from insulin-sensitive to insulin-resistant more rapidly as body fat rises. Monitoring fasting insulin and two-hour post-load glucose provides earlier warning than HbA1c alone for this genotype.

The finding that p58 isoform reduction alters IGF2 pathway activity in both adipose and islet tissue suggests that interventions supporting insulin signaling efficiency (adequate chromium, zinc, and inositol as cofactors; low-glycaemic dietary pattern) are mechanistically relevant, not generic.

Interactions

The most clinically important interaction for this variant is with TCF7L2 rs7903146, the strongest single T2D GWAS signal. Both IGF2BP2 and TCF7L2 act in beta cell regulatory circuits — TCF7L2 through Wnt signaling and IGF2BP2 through IGF2/PDX1 axis. Carriers of risk alleles at both loci may carry compounded beta cell dysfunction, warranting especially proactive insulin secretory reserve monitoring.

rs11705701 is in partial but not complete linkage disequilibrium with rs4402960, the originally reported IGF2BP2 GWAS hit from the first wave of T2D genome-wide studies. In Mexican Americans, the two SNPs are in strong LD (D′≈1, r²≈0.95), but they tag different functional effects in some other populations, suggesting each contributes independently to metabolic risk.

The CD58 gene¹¹ CD58 gene
CD58 encodes LFA-3 (Lymphocyte Function-Associated Antigen 3), a cell-surface glycoprotein that binds CD2 on T cells to stabilise the immune synapse and promote regulatory T cell expansion harbours a cluster of intronic variants in its first intron that collectively regulate LFA-3 expression and multiple sclerosis susceptibility. The rs12044852 C/A polymorphism is one of three strongly associated markers in this locus (alongside rs2300747 and rs1335532), linked by very high linkage disequilibrium (r²=0.929 between rs12044852 and rs2300747). What distinguishes rs12044852 from its LD partner is its documented pharmacogenomic relevance: the CC genotype not only elevates MS risk but also predicts poor response to interferon-beta, the most widely prescribed first-line MS therapy.

The Mechanism

Like its LD partner rs2300747, the rs12044852 C/A polymorphism sits within the first intron of CD58 and modulates LFA-3 (CD58) mRNA expression²² LFA-3 (CD58) mRNA expression
Higher LFA-3 expression strengthens CD2-mediated costimulatory signalling in regulatory T cells (Tregs), promoting FoxP3 expression and self-tolerance. The protective A allele is associated with higher CD58 mRNA levels, mirroring the effect seen at the companion rs2300747(G) allele. Carriers of the A allele therefore have a more robust CD2–LFA-3 interaction, driving stronger Treg induction and better immune self-regulation.

For IFN-beta response, the mechanism likely connects through CD58's role in modulating T-regulatory cell potency³³ T-regulatory cell potency
IFN-beta partly exerts its anti-inflammatory effect in MS by augmenting Treg numbers and function; impaired baseline Treg activity from CD58 deficiency may blunt this therapeutic leverage. Patients who start with a CD58-deficient immune set-point (CC genotype) may derive less clinical benefit from an immunomodulatory agent that depends on intact Treg circuitry. The shared intronic haplotype block also encodes hsa-miR-548ac⁴⁴ hsa-miR-548ac
A microRNA co-transcribed from the CD58 first intron; the risk haplotype raises miR-548ac and lowers CD58 mRNA from the same primary transcript via altered Drosha cleavage, whose elevated expression in risk carriers may further suppress immunoregulatory target genes relevant to IFN-beta signalling.

The Evidence

MS susceptibility: A case-control study by Omrani et al. 2015⁵⁵ Omrani et al. 2015
200 RRMS patients vs 200 healthy controls, Iranian population; genotyping by PCR-SSP; Hardy-Weinberg confirmed in both groups found the CC genotype in 83.5% of MS patients versus 69.5% of controls, yielding an OR of 2.22 (P=0.001). The A allele (minor allele, ~10% in Europeans) acts protectively: AA individuals were significantly less likely to have MS. This mirrors the pattern at the LD-partner rs2300747, where the G (minor) allele is protective, and is consistent with the shared haplotype interpretation that the same regulatory region drives both associations.

Independent replication by Booth et al. 2008 in 1,134 Australian MS cases and 1,265 controls⁶⁶ Booth et al. 2008 in 1,134 Australian MS cases and 1,265 controls confirmed CD58 rs12044852 as a susceptibility variant (P=0.042). The broader CD58 locus was confirmed at genome-wide significance (P=4×10⁻⁹) by Hoppenbrouwers et al. 2009⁷⁷ Hoppenbrouwers et al. 2009 and is among the 57 confirmed MS susceptibility loci in the large Sawcer et al. 2011 Nature GWAS⁸⁸ Sawcer et al. 2011 Nature GWAS
9,772 cases collected by 23 research groups across 15 countries.

IFN-beta response: Among 120 relapsing-remitting MS patients receiving IFN-beta therapy and followed over two years, Omrani et al.⁹⁹ Omrani et al. found striking genotype-stratified differences in Multiple Sclerosis Severity Score trajectory. The ΔMSSS (change from baseline) was 0.44 for CC carriers — the worst outcome group — compared with 0.03 for AC carriers (best responders) and 0.11 for AA carriers. The association between CC genotype and poor IFN-beta response was statistically significant (P<0.05). This is the first pharmacogenomic annotation of rs12044852 and represents the primary clinical utility distinguishing it from rs2300747.

Population genetics: the C allele is very common in Europeans (~90%) and Africans (~93%), but notably less so in East Asians (~42%), paralleling the lower MS burden in East Asian populations and matching the inverse pattern seen at rs2300747's protective G allele.

Practical Actions

For CC carriers — the large majority of European-descent individuals — the two key clinical implications are: (1) modest but real elevation of MS susceptibility requiring awareness of early warning signs and attention to modifiable risk factors, especially vitamin D; and (2) if MS develops and IFN-beta therapy is being considered, this genotype signals a higher likelihood of suboptimal therapeutic response. Discussing this with a neurologist before committing to IFN-beta over alternative disease-modifying therapies (natalizumab, ocrelizumab, dimethyl fumarate, or sphingosine-1-phosphate modulators) is worthwhile.

For AC or AA carriers, the protective A allele suggests better IFN-beta response and lower baseline MS susceptibility, though the A allele is rare (~10% in Europeans) and the AA genotype is uncommon (~1%).

Vitamin D optimisation is the strongest modifiable lever for all genotypes: sufficiency independently supports FoxP3 expression and Treg function through the vitamin D receptor pathway, partially compensating for reduced LFA-3-mediated Treg support.

Interactions

Within the CD58 locus, rs12044852 and rs2300747 are in near-complete LD (r²=0.929) and almost certainly tag the same functional haplotype. An individual's risk at one predicts their risk at the other. The companion variant rs1335532 is also in strong LD and appears to anchor the miR-548ac regulatory mechanism described by Hecker et al. 2019¹⁰¹⁰ Hecker et al. 2019.

The CD58 costimulatory axis intersects with rs6897932 (IL7R), which regulates T-cell homeostasis and Treg survival, and with PTPN22 rs2476601, which lowers the TCR activation threshold. Individuals carrying high-risk alleles across these loci face compounding impairments to immune self-tolerance. The pharmacogenomic IFN-beta response signal at rs12044852 adds a third dimension: genetic background may influence not just who develops MS but how well they respond to its first-line treatment.

CHI3L1 encodes YKL-40¹¹ CHI3L1 encodes YKL-40
YKL-40 is a chitinase-like protein secreted by macrophages, neutrophils, bronchial epithelial cells, and smooth muscle cells; it drives airway inflammation, bronchial wall remodeling, and smooth muscle proliferation independent of classical eosinophilic Th2 pathways, making it one of the most clinically relevant biomarkers of non-T2, severe asthma. Most genetic studies of CHI3L1 have focused on the promoter variant rs4950928 (-131C>G), which modulates transcription start site activity and produces the largest common-variant effect on circulating YKL-40 levels. rs12141494 sits in intron 6 of CHI3L1 at chr1:203,182,297 (GRCh38), a region that modulates YKL-40 expression through a distinct mechanism — and crucially, does so independently of the promoter variant.

The Mechanism

Intronic variants can regulate gene expression through splicing enhancer/silencer sequences, effects on transcription elongation, or by altering the binding of regulatory RNA or chromatin-modifying complexes to the pre-mRNA. rs12141494 is a G>A transition on the plus strand; because CHI3L1 is encoded on the minus strand, this corresponds to a C>T change on the coding strand. In specific transcript isoforms (XP_047298829.1 and XP_047298835.1), this position falls at a coding boundary and produces a proline-to-serine missense change (Pro205Ser and Pro199Ser respectively), suggesting that the intron 6 position may have functional consequences beyond pure splicing regulation. However, in the canonical CHI3L1 transcript the variant is classified as an intron variant by dbSNP. Conditional analysis in the Gomez et al. 2015 study²² Conditional analysis in the Gomez et al. 2015 study
Jose L Gomez et al., Yale and SARP cohorts, n=1,178 asthmatic subjects of European ancestry; both cohorts analyzed independently and results intersected confirmed that rs12141494 influences YKL-40 levels and FEV1 independently of rs4950928, establishing it as a second, distinct CHI3L1 regulatory locus.

The Evidence

The primary evidence for rs12141494 comes from a two-cohort study of asthma severity and airway YKL-40 expression³³ two-cohort study of asthma severity and airway YKL-40 expression
Gomez et al. J Allergy Clin Immunol 2015; 259 Yale Center for Asthma and Airways Disease subjects and 919 SARP (Severe Asthma Research Program) subjects; all of European ancestry. Of 15 CHI3L1 SNPs associated with FEV1, serum YKL-40, or both, rs12141494 (intron 6) was the only SNP in European-ancestry subjects that was consistently associated in both cohorts with serum YKL-40 levels and post-bronchodilator FEV1. The A allele at rs12141494 was associated with higher airway YKL-40 expression and worse asthma severity (P≤0.05). The G allele was associated with lower YKL-40 expression and higher FEV1 percent predicted, i.e. better preserved lung function.

The clinical importance of YKL-40 as a severity biomarker is well-established. A meta-analysis of 17 studies covering 5,696 subjects⁴⁴ meta-analysis of 17 studies covering 5,696 subjects
Jin et al. Sleep Breath 2022 confirmed that serum YKL-40 is significantly elevated in asthma versus controls, rising further with severity and acute exacerbations. YKL-40 correlates specifically with bronchial wall thickening (r=0.45), blood neutrophils (r=0.63), and exhaled nitric oxide (r=0.48) in therapy-resistant pediatric asthma⁵⁵ bronchial wall thickening (r=0.45), blood neutrophils (r=0.63), and exhaled nitric oxide (r=0.48) in therapy-resistant pediatric asthma
Konradsen et al. J Allergy Clin Immunol 2013; therapy-resistant vs controlled asthma; serum YKL-40 19.2 vs 13.8 ng/mL, P=0.03 — all markers of active airway remodeling rather than simple allergen sensitization. In a 2023 phenotype review⁶⁶ 2023 phenotype review
Specjalski et al. Front Med 2023, YKL-40 was highest in severe neutrophilic and obesity-associated asthma, correlating with therapy resistance, exacerbation frequency, and FEV1 decline.

Practical Actions

Carriers of the A allele at rs12141494 have a genetically elevated YKL-40 set-point that drives airway remodeling independently of promoter-driven YKL-40 regulation. For asthmatic A-allele carriers, serum YKL-40 measurement provides direct insight into the biological activity of this genetic predisposition. Because YKL-40 elevation is relatively steroid-insensitive (it marks non-T2 remodeling rather than eosinophilic inflammation), standard inhaled corticosteroid escalation may undertreat the remodeling process it drives. Exposure to occupational dust, mold, and biomass smoke are the principal environmental triggers documented to amplify YKL-40-driven airway remodeling, and are specifically relevant for A-allele carriers with occupational asthma or indoor air quality concerns.

Interactions

rs12141494 operates independently of the CHI3L1 promoter variant rs4950928, which is already in the GeneOps database. Carriers of the A allele at rs12141494 who also carry the C allele at rs4950928 are doubly predisposed to elevated YKL-40 through two mechanistically distinct routes: reduced transcriptional suppression (rs4950928) and altered intron 6 splicing or transcript regulation (rs12141494). The SARP/Yale study specifically confirmed the independence of these effects through conditional analysis; having risk alleles at both loci would be expected to produce the highest YKL-40 burden of any CHI3L1 genotype combination.

The SLC11A2 gene encodes Divalent Metal Transporter 1 (DMT1)¹¹ Divalent Metal Transporter 1 (DMT1)
also known as NRAMP2; the primary transporter for ferrous iron across intestinal epithelial cells and from endosomes into the cytosol, the most important protein controlling how much dietary iron enters your body. Located at chromosome 12q13.12, SLC11A2 is expressed in the duodenum, liver, kidney, and — critically for diabetes risk — in pancreatic beta cells, where iron availability directly governs insulin production and secretion. The intronic variant rs12304921 (G allele, ~17% in Europeans) lies within a regulatory region of the gene and has been genotyped in multiple type 2 diabetes (T2DM) genome-wide association studies, pointing to the SLC11A2 locus as a contributor to diabetes susceptibility through the iron-homeostasis pathway.

The Mechanism

DMT1 operates as the gatekeeper for non-heme dietary iron absorption in the duodenum: it transports ferrous iron (Fe²⁺) across the apical brush border membrane of enterocytes. Inside the cell, ferroportin then exports iron into the bloodstream. The balance between DMT1 expression (import) and ferroportin (export) determines systemic iron load. Critically, the SLC11A2 gene produces two major isoforms via alternative 3′ splicing: one containing an iron-responsive element (IRE)²² iron-responsive element (IRE)
a stem-loop structure in the 3′ UTR that stabilizes the mRNA when cellular iron is low, allowing compensatory upregulation of iron absorption in its 3′ UTR, and one lacking this element. Intronic variants near splice regulatory sequences — as rs12304921 may be — can shift the ratio between these two isoforms, altering the body's ability to sense and respond to iron status. When the IRE-containing isoform is suppressed, the body loses its adaptive capacity to upregulate iron absorption during deficiency — or, conversely, to downregulate it during overload.

Beta cells are particularly vulnerable to iron dysregulation. Pancreatic beta cells express high levels of DMT1 and accumulate iron more readily than neighboring alpha cells due to low ferroportin expression. Iron deprivation in isolated islets reduces glucose-stimulated insulin secretion by 45%³³ Iron deprivation in isolated islets reduces glucose-stimulated insulin secretion by 45%
Martínez-García et al. Cell Metab 2020; n=purified human islet subsets, while iron excess causes oxidative damage via Fenton chemistry, impairing glucose sensing and triggering beta-cell apoptosis. Transcriptome analyses comparing T2DM and control tissue have found that SLC11A2 is significantly downregulated in T2DM samples, and its expression level correlates positively with 113 of 154 insulin-secretion genes — suggesting that disrupted DMT1 function contributes to the beta-cell failure characteristic of T2DM.

The Evidence

rs12304921 was included in the genotyping arrays of several landmark T2DM GWAS studies, including the Wellcome Trust Case Control Consortium (WTCCC) 7-disease GWAS⁴⁴ Wellcome Trust Case Control Consortium (WTCCC) 7-disease GWAS
n=14,000 cases, 3,000 controls across seven diseases including T2DM and a cumulative risk SNP study in Han Chinese⁵⁵ cumulative risk SNP study in Han Chinese
Qian et al. PLoS One 2015; n=996 T2DM cases, 998 controls. These studies establish that the SLC11A2 locus is relevant to T2DM genetic architecture across diverse populations, particularly given the notably higher G allele frequency in East Asian populations (~50%) compared to Europeans (~17%).

A Turkish case-control study examined SLC11A2 intronic polymorphisms directly in 100 T2DM patients versus 100 healthy controls and found that the homozygous risk genotype was significantly associated with T2DM risk under a recessive model (P=0.030 for homozygotes; P=0.037 recessive model)⁶⁶ (P=0.030 for homozygotes; P=0.037 recessive model)
Ozbayer et al. J Genet 2018, PMID 30555088, with the risk genotype carriers showing higher blood iron levels — consistent with disrupted iron regulation as the underlying mechanism.

At the gene-expression level, a transcriptome meta-analysis found that SLC11A2 and TFRC (transferrin receptor) are significantly downregulated in T2DM tissue⁷⁷ SLC11A2 and TFRC (transferrin receptor) are significantly downregulated in T2DM tissue
Yang et al. Diabetol Metab Syndr 2023, with SLC11A2 expression positively correlating with 73% of insulin-secretion genes. A meta-analysis of iron biomarkers and T2DM found that elevated serum ferritin (a marker of iron stores) is associated with a 70% increased T2DM risk, and interventional phlebotomy studies show that reducing iron stores improves insulin sensitivity and beta-cell function in pre-diabetic individuals.

At this time, rs12304921 has not reached genome-wide significance as a standalone T2DM locus, and the evidence is classified as emerging. The biological mechanism connecting SLC11A2 to T2DM is well-established; the specific contribution of this intronic variant requires further functional characterization.

Practical Implications

G allele carriers have potential for altered iron absorption regulation, which may manifest as higher baseline iron stores or impaired adaptive upregulation during iron deficiency. Given the U-shaped relationship between iron status and T2DM risk — both very low and very high iron are harmful — monitoring serum ferritin is the key actionable insight. GG homozygotes carry the greatest potential for altered iron homeostasis. Avoiding supplemental iron unless deficiency is confirmed by blood tests is particularly important, since excess iron loads the pancreatic beta cells with ferrous iron that generates oxidative damage.

Interactions

SLC11A2 function interacts with several other iron-homeostasis genes: HFE (rs1799945, C282Y) mutations cause hereditary hemochromatosis through hepcidin dysregulation upstream of DMT1; TMPRSS6 (rs855791) regulates hepcidin synthesis, the master iron hormone that suppresses DMT1 at the duodenum. Carriers of both rs12304921 G and HFE C282Y may accumulate iron more rapidly than either variant alone predicts, as DMT1 dysregulation combined with reduced hepcidin signaling removes two separate brakes on iron absorption. These potential gene-gene interactions warrant a combined monitoring approach in carriers.

Apolipoprotein B-100 (ApoB) is the structural backbone of LDL particles — every LDL particle carries exactly one ApoB-100 protein, and it is this protein that docks with the LDL receptor on liver cells to clear LDL from the bloodstream. The rs12713559 variant causes a cysteine to replace an arginine at position 3558 of the ApoB protein, in the segment responsible for LDL receptor binding. This disrupts LDL clearance, but to a degree that varies considerably between individuals.

The Mechanism

The p.Arg3558Cys substitution (historically called R3531C in earlier numbering systems) sits within the proposed LDL receptor-binding domain of ApoB. Arginine at position 3558 contributes to the cluster of positively charged residues that interact electrostatically with the LDL receptor. Replacing it with cysteine introduces a sulfhydryl group and removes a positive charge, impairing the ApoB-LDL receptor interaction.

Functional assays¹¹ Functional assays
Pullinger CR et al. Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest, 1995 show that LDL particles from R3558C heterozygotes bind to the LDL receptor at roughly 50-63% of normal affinity. In competitive binding assays using U937 cells, the defective particles were 74% as effective as normal LDL and accumulated preferentially compared to the wild-type allotype — meaning mutant LDL persists longer in circulation.

The Evidence

The discovery report²² discovery report
Pullinger CR et al. J Clin Invest, 1995 identified the variant in two unrelated families; all eight carriers showed elevated cholesterol (mean 240 mg/dL) versus unaffected relatives (185 mg/dL). The gene sits on the minus strand; the coding-strand change is C>T at position 10672 of NM_000384.3.

A larger kindred study³³ larger kindred study
Ouguerram K et al. The apolipoprotein B R3531C mutation. Characteristics of 24 subjects from 9 kindreds. J Lipid Res, 1999 of 24 carriers from 9 kindreds confirmed the binding deficit but found highly variable LDL cholesterol expression, modulated by environmental and other genetic factors.

Crucially, a large population-based study⁴⁴ population-based study
Tybjaerg-Hansen A et al. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. NEJM, 1998 of 9,255 Danish individuals found R3558C heterozygotes (0.08% prevalence) did not have higher-than-normal plasma cholesterol levels, and the association with ischemic heart disease was not significant (OR 1.4, 95% CI 0.2-11, p=0.54). This contrasts sharply with the well-characterized R3500Q variant (rs5742904), which is 10-fold more prevalent and is a well-established cause of familial defective apolipoprotein B (FDB) with OR 7.0 for ischemic heart disease.

A family-based segregation study⁵⁵ family-based segregation study
Rabes JP et al. R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia. Atherosclerosis, 2000 found that 6 of 10 R3558C carriers had normal cholesterol, with the mean cholesterol not significantly different between carriers and non-carriers. A co-segregating LDLR mutation was the primary driver of hypercholesterolemia in that family, with R3558C potentially acting as a modifier.

ClinVar now records 14 of 18 submissions as uncertain significance (last updated February 2026). The 1995 OMIM pathogenic entry and one Italian laboratory's "likely pathogenic" call are flagged as not meeting current evidence criteria.

Practical Actions

Because the clinical significance of this variant remains genuinely uncertain, the most appropriate response is cardiovascular risk monitoring through regular lipid panels, not preemptive treatment. Many carriers have normal cholesterol. If LDL is elevated, standard FH-adjacent management applies: dietary saturated fat restriction and statin therapy if needed. The variant does not affect statin mechanism — statins upregulate the LDL receptor, so even with reduced ApoB-LDL receptor affinity, statin response should be intact.

If you are heterozygous for this variant and have elevated LDL cholesterol, genetic testing for LDLR mutations is warranted, as co-occurring LDLR mutations may be driving the lipid phenotype.

Interactions

The clinically important interaction is between rs12713559 and LDLR mutations (not catalogued in this database). Rabes et al. (2000) found that R3558C alone did not cause hypercholesterolemia but may amplify the effect of a concurrent LDLR defect. The related and far more common APOB R3500Q variant (rs5742904) is the canonical cause of familial defective apolipoprotein B; if you also carry APOE E4 (rs429358), independent cardiovascular risk factors stack.